폐섬유증 바이오마커 시장 : 검사 유형, 적응증, 최종사용자별 - 세계 예측(2024-2032년)

Global Pulmonary Fibrosis Biomarkers Market Size will witness 4.4% CAGR between 2024 and 2032 due to rising research and developments in the field. As understanding of pulmonary fibrosis deepens, there is a growing need for biomarkers that can accurately diagnose the disease, monitor its progression, and predict treatment outcomes. For instance, in November 2023, researchers at Genentech Inc., spearheaded by a team of scientists, were endeavoring to identify biomarkers for idiopathic pulmonary fibrosis (IPF), a severe lung disease. Their focus lies in exploring whether bioactive lipid species hold potential in predicting the progression of IPF. Margaret Neighbors, a senior scientist at Genentech, revealed that their initial research efforts were centered on chronic obstructive pulmonary disease (COPD).

Advanced biomarkers enable early detection and personalized treatment strategies, improving patient care and prognosis. Moreover, ongoing research efforts are uncovering novel biomarkers with potential diagnostic and prognostic utility, driving market growth. With the global burden of pulmonary fibrosis on the rise and a growing emphasis on precision medicine, the demand for reliable biomarkers is expected to continue growing, shaping the future of the Pulmonary Fibrosis Biomarkers Market.

The overall Pulmonary Fibrosis Biomarkers Industry is classified based on the test type, indication, end-user, and region.

The blood test segment will undergo groundbreaking development from 2024 to 2032. Blood-based biomarkers offer a non-invasive and accessible means of assessing pulmonary fibrosis progression, aiding in treatment decision-making and patient management. As research continues to identify novel blood biomarkers associated with disease severity and prognosis, the demand for reliable blood tests is escalating. Healthcare providers are increasingly incorporating blood-based biomarker testing into their diagnostic algorithms, fueling the expansion of the Pulmonary Fibrosis Biomarkers Market and offering hope for improved outcomes for patients battling this debilitating lung condition.

The pulmonary fibrosis biomarkers share from the drug induced pulmonary fibrosis segment will register a noteworthy CAGR from 2024 to 2032. As adverse drug reactions continue to pose a significant concern, there is a pressing need for biomarkers that can accurately detect and monitor drug-induced lung injury. These biomarkers play a crucial role in identifying patients at risk, enabling early intervention, and facilitating personalized treatment approaches. With ongoing research efforts aimed at identifying specific biomarkers associated with drug-induced pulmonary fibrosis, the demand for innovative diagnostic tools is on the rise, driving growth in the Pulmonary Fibrosis Biomarkers Market and improving patient care outcomes.

Europe pulmonary fibrosis biomarkers market will showcase a commendable CAGR from 2024 to 2032. With a rising prevalence of pulmonary fibrosis cases and a need for early diagnosis and targeted treatment, there is a heightened demand for biomarkers that can accurately detect and monitor the disease progression. European regulatory bodies are also encouraging the development and adoption of biomarker-based diagnostic tools, further fueling market growth. As a result, the Pulmonary Fibrosis Biomarkers Market in Europe is witnessing significant expansion, presenting lucrative opportunities for manufacturers and researchers to address the region's evolving healthcare needs.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of pulmonary fibrosis
    • 3.2.1.2 Increasing advancements in biomarker discovery technologies
    • 3.2.1.3 Rising government initiatives and policies
    • 3.2.1.4 Increasing use of biomarkers
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost associated with biomarker tests and diagnostics
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix

Chapter 5 Market Estimates and Forecast, By Test Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Blood test
  • 5.2.1 C-reactive protein test
  • 5.2.2 Antibody testing kits
    • 5.2.2.1 Antinuclear antibodies (ANA) test
    • 5.2.2.2 Anti-CCP antibody test
  • 5.2.3 ESR test and CBC
  • 5.2.4 Pulmonary function test
  • 5.2.5 Imaging test
    • 5.2.5.1 X-rays scans
    • 5.2.5.2 HRCT scans
  • 5.2.6 Lung biopsy
  • 5.2.7 Other test types

Chapter 6 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Idiopathic pulmonary fibrosis (IPF)
• 6.3 Rheumatoid arthritis interstitial lung disease (RA-ILD)
• 6.4 Drug-induced pulmonary fibrosis
• 6.5 COVID-19-related pulmonary fibrosis
• 6.6 Pneumoconiosis
• 6.7 Sarcoidosis
• 6.8 Other indications

Chapter 7 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Diagnostic laboratories
• 7.5 Research & academic institutes
• 7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Biocartis NV
• 9.2 Biogen Inc.
• 9.3 Bristol-Myers Squibb Company
• 9.4 F. Hoffman-La Roche Ltd
• 9.5 Galapagos NV
• 9.6 Lung Therapeutics, Inc.
• 9.7 Myriad Genetics, Inc.
• 9.8 OptiKira LLC
• 9.9 Respivant Sciences GmbH
• 9.10 Veracyte, Inc.